Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer (Q24307748)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

estrogen-receptor positive breast cancer

5 March 2020

main subject

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Bhupinder Pal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Matthew E Ritchie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Louisa Phillipson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Christopher J. Burns

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Bruce Mann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Geoffrey J. Lindeman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

12

Jane E Visvader

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

François Vaillant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Lily Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Kelsey Breslin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michael Christie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Gordon K Smyth

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

120-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

SnapShot: breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

ABT-199: taking dead aim at BCL-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Programmed anuclear cell death delimits platelet life span.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Apoptosis therapy: driving cancers down the road to ruin

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

The Bcl-2 family: roles in cell survival and oncogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Aberrant expression of apoptosis-related molecules in endometriosis: a possible mechanism underlying the pathogenesis of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

Targeting the B-cell lymphoma/leukemia 2 family in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.06.002

7 January 2021

10.1016/J.CCR.2013.06.002

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

3375702

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3375702

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

3375702

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845444%20AND%20SRC:MED&resulttype=core&format=json